Alexis M. Bachmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alexis M. Bachmann has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Dermot F. Reilly
Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts
1 shared publication - Ellen Broeckx
Janssen Research and Development, LLC 2 , Raritan, NJ, USA
1 shared publication - Giacomo von Alvensleben
Laboratory of Integrative Systems Physiology, Ecole Polytechnique Federale de Lausanne
1 shared publication - Giorgia Benegiamo
Laboratory of Integrative Systems Physiology, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
1 shared publication - Jean-David Morel
Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
1 shared publication - Jing Ying Ma
Janssen Research and Development, LLC 2 , Raritan, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 14 February 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (4)
The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression
Non-alcoholic steatohepatitis (NASH) is a global health concern without treatment. The challenge in finding effective therapies is due to the lack of good mouse models and the complexity of the disease, characterized by gene–environment interactions. We tested the susceptibility of seven mouse strains to develop NASH. The severity of the clinical phenotypes observed varied widely across strains. PWK/PhJ mice were the most prone to develop hepatic inflammation and the only strain to progress to NASH with extensive fibrosis, while CAST/EiJ mice were completely resistant. Levels of mitochondrial transcripts and proteins as well as mitochondrial function were robustly reduced specifically in the liver of PWK/PhJ mice, suggesting a central role of mitochondrial dysfunction in NASH progression. Importantly, the NASH gene expression profile of PWK/PhJ mice had the highest overlap with the human NASH signature. Our study exposes the limitations of using a single mouse genetic background in metabolic studies and describes a novel NASH mouse model with features of the human NASH.
- 14 February 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (4)
Open AccessThe genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression
Non-alcoholic steatohepatitis (NASH) is a global health concern without treatment. The challenge in finding effective therapies is due to the lack of good mouse models and the complexity of the disease, characterized by gene–environment interactions. We tested the susceptibility of seven mouse strains to develop NASH. The severity of the clinical phenotypes observed varied widely across strains. PWK/PhJ mice were the most prone to develop hepatic inflammation and the only strain to progress to NASH with extensive fibrosis, while CAST/EiJ mice were completely resistant. Levels of mitochondrial transcripts and proteins as well as mitochondrial function were robustly reduced specifically in the liver of PWK/PhJ mice, suggesting a central role of mitochondrial dysfunction in NASH progression. Importantly, the NASH gene expression profile of PWK/PhJ mice had the highest overlap with the human NASH signature. Our study exposes the limitations of using a single mouse genetic background in metabolic studies and describes a novel NASH mouse model with features of the human NASH.